Breast cancer patients often suffer from disease relapse and metastasis due to the presence of breast cancer stem-like cells (BCSCs). Numerous studies have reported that high levels of inflammatory factors, including tumor necrosis factor alpha (TNF-α), promote BCSCs. However, the mechanism by which tnf-α promotes BCSCs is unclear. In this study, we demonstrate that TNF-α up-regulates TAZ, a transcriptional co-activator promoting BcSc self-renewal capacity in human breast cancer cell lines. Depletion of TAZ abrogated the increase in BCSCs mediated by TNF-α. TAZ is induced by TNF-α through the non-canonical nf-κB pathway, and our findings suggest that TAZ plays a crucial role in inflammatory factor-promoted breast cancer stemness and could serve as a promising therapeutic target.
positivity and CD44 high CD24 low are generally considered two of the most frequently used identification makers of BCSCs 21 . It has been reported that CD44 positive/high expression is responsible for maintenance of multipotency, proliferation, and migration 22 , CD24 negative/low expression is responsible for cell growth and migration 23 , and ALDH1 positive/high expression is responsible for cell proliferation and stemness 24 . In addition, mammosphere formation can also identify breast cancer stem-like cells, which is based on the ability of BCSCs to propagate as multicellular spheroids in suspension culture. Currently, BCSCs have been implicated in breast cancer relapse and metastasis due to their resistance to chemo-and radiotherapies and tumorigenic properties 25, 26 . However, there are currently no effective therapeutic strategies to specifically eliminate BCSCs.
TAZ, a transcriptional co-activator with a PDZ binding motif, has been implicated in sustaining BCSCs. A previous study demonstrated that TAZ confers self-renewal and tumor initiation capacity to non-BCSCs 27 . As a main effector of the Hippo pathway, TAZ interacts with TEADs to activate transcription of target genes, including CYR61, CTGF, and BIRC5 [28] [29] [30] . High TAZ expression is associated with low survival rates in breast cancer patients 27 . Our previous study suggested that TAZ depletion dramatically suppresses basal type breast cancer HCC1937 growth in vivo 31 . While regulation of TAZ at the post-translational modification level is becoming increasingly clear, knowledge of TAZ regulation at the transcriptional level is relatively limited. To date, four transcription factors, RelA 32 , HIF-1 33 , SRF and MRTF 34 , have been reported to promote TAZ transcription.
Herein, we illustrate that TNF-α increases the percentage of BCSCs and TAZ expression levels in human breast cancer cell lines, and depletion of TAZ abrogates this phenotype. We further demonstrate that TAZ is induced by TNF-α through the non-canonical NF-κB pathway. Our findings indicate that inflammatory factors such as TNF-α increases stemness via up-regulation of TAZ transcription through non-canonical NF-κB pathway. We suggest that TAZ plays a crucial role in TNF-α-promoted breast cancer stemness and could serve as a promising therapeutic target.
Results

tnf-α increases breast cancer stem-like cells and up-regulates TAZ transcription in breast cancer cell lines.
Two breast cancer cell lines, MCF7 and MDA-MB-468, were used in this study. MCF7 is ERα+ breast cancer cell line and MDA-MB-468 is triple-negative breast cancer (TNBC) cell line. It has been reported that TNBC cells are more like cancer stem cells (CSC) in terms of gene expression signature 35 .
TNF-α is well known as an important effector in breast cancer 36 . To confirm whether TNF-α promotes breast cancer stem-like cells, we cultured MCF7 cells under non-adherent culture conditions to foster mammosphere formation and found that TNF-α addition (10 ng/ml) significantly increased the number of mammospheres ( Fig. 1A,B ). We further performed ALDEFLUOR assays in MCF7 and MDA-MB-468 cell lines with or without TNF-α treatment and found that TNF-α significantly increased the population of ALDH positive cells in both MCF7 (Fig. 1C ,D) and MDA-MB-468 ( Fig. S1A,B) cell lines. We also tested the percentage of CD44+ and CD24− cells in these two cell lines. The percentage of CD44+ cells increased significantly in MCF7 (Figs. 1E and S1C). All MCF7 cells are CD24 positive, and all MDA-MB-468 cells are both CD44 and CD24 positive ( Fig. S1C,D) , as previously reported 37, 38 . We found that CD24 was increased in MCF7 cells but decreased in MDA-MB-468 cells after TNF-α treatment ( Fig. S1C,D) .
Next, we demonstrated that TNF-α promotes protein expression of TAZ, a transcriptional coactivator necessary for self-renewal and tumor initiation in BCSCs 27 in MCF7 ( Fig. 1F) . Similar results were observed in MDA-MB-468 cells ( Fig. S1E ). Because YAP shares a similar regulatory mechanism with TAZ in the Hippo pathway, we tested whether TNF-α also induces YAP. However, YAP was not induced by TNF-α in either MCF7 or MDA-MB-468 cells ( Fig. S2C,D) .
To characterize the potential mechanism by which TNF-α induces TAZ, we first measured TAZ mRNA levels by RT-qPCR. Our results showed that TNF-α significantly up-regulates mRNA levels of both TAZ and its target gene Cyr61 in both MCF7 ( Fig. 1G ) and MDA-MB-468 ( Fig. S1D ) cells. We also measured TAZ protein half-life and found that TNF-α does not affect TAZ protein stability ( Fig. S2A,B ). We concluded that TNF-α up-regulates TAZ expression predominately at the transcriptional level rather than the post-transcriptional level.
TAZ mediates TNF-α-increased the proportion of BCSCs. To explore whether TNF-α promotes
BCSCs via up-regulation of TAZ, we knocked down TAZ using two individual siRNAs in MCF7 cells and assessed BCSC levels. TNF-α-induced mammosphere increase was completely abolished when TAZ was knocked down ( Fig. 2A-C ). In agreement with this, TAZ knockdown significantly blocked TNF-α-induced ALDH positive cell increase in MCF7 cells ( Fig. 2D) . Similar results were observed in MDA-MB-468 cells ( Fig. S3A -C). TAZ knockdown also significantly decreased the TNF-α induced increase of CD44+ cells in MCF7 ( Fig. S3D ,E). TAZ knockdown did not blocked the TNF-α mediated the CD24 expression changes in both cell lines ( Fig. S3G ).
These results indicate that TAZ may be necessary for TNF-α-increased the proportion of BCSCs.
tnf-α induces TAZ transcription through the non-canonical NF-κB pathway. TNF-α is a
well-known activator of the canonical NF-κB pathway, and RelA regulates TAZ transcription in mesenchymal stem cells 32 . To further characterize the mechanism by which TNF-α induces TAZ transcription, we first tested whether RelA is responsible for TNF-α induction of TAZ transcription. After RelA knockdown, TAZ was still induced by TNF-α ( Fig. 3A ). Next, we knocked down other transcriptional factors in the canonical NF-κB pathway, including p105 and RelB. However, knockdown of neither p105 nor RelB suppressed TAZ induction by TNF-α ( Fig. 3B,C) . These results indicate that TNF-α may not induce TAZ transcription via the canonical NF-κB pathway.
Subsequently, we knocked down IKKα and found that this manipulation suppressed TNF-α-induced TAZ and CYR61 up-regulation (Figs. 4A and S4A). IKKα plays a crucial role in the non-canonical NF-κB pathway. Next, we knocked down transcription factor p100 in MCF7 and MDA-MB-468 cells and found that p100 depletion also inhibited TNF-α-induced TAZ and CYR61 up-regulation at both the protein and mRNA level (Figs. 4B,E and S4B,D). When the non-canonical NF-κB pathway is activated, p100 is processed through the proteasome 39 . We used MG132, a proteasome inhibitor, to pretreat cells before TNF-α stimulation. As expected, MG132 stabilized TAZ protein but suppressed TNFα-induced TAZ up-regulation in both MCF7 and MDA-MB-468 cells (Figs. 4C and S4C). We also pretreated cells with the IKKα inhibitor BAY11-7082 after TNF-α stimulation. Similar to MG132, BAY11-7082 inhibited TNF-α-induced TAZ and CYR61 increase in both MCF7 and MDA-MB-468 cells (Figs. 4D and S4E).Then we preformed ALDEFLUOR assays and found that IKKα silencing suppressed TNF-α-induced ALDH positive cell increase in both MCF7 and MDA-MB-468 cells (Fig. S4F,G) . At the same time, we also detected CD44 and CD24 expression levels in these cells. Knockdown of either IKKα or p100 decreased the TNF-α induced increase of CD44+ cells in MCF7 ( Fig. S4G,H) . In MDA-MB-468 cells, IKKα and p100 knockdown had no significant effect on the expression of CD24 ( Fig. S4G ,I).
We next silenced p100 in MCF7 cells and found significant suppression of TNF-α-increased the proportion of mammosphere ( Fig. 4F-G) . Furthermore, TNF-α promoted not only p100 protein expression, but also its processing ( Fig. 4B ). p100 knockdown suppressed p100 processing into p52, as well as inhibiting TAZ and CYR61 induction by TNF-α ( Fig. 4B ). These results further support the notion that TNF-α up-regulates TAZ through the non-canonical NF-κB pathway. p52 binds to the TAZ promoter to initiate TAZ transcription through TNF-α-induced p100 expression and processing. To further confirm that TNF-α induces TAZ through non-canonical NF-κB signaling, we treated MCF7 and MDA-MB-468 cells with TNF-α and examined p100 processing. We observed that p100 processing was enhanced with time as p52 gradually increased ( Fig. 5A ). Additionally, we tested whether RANKL, a typical non-canonical NF-κB pathway activator, can induce TAZ. Similar to TNF-α, RANKL also up-regulates TAZ and CYR61 through enhancing p100 processing in MDA-MB-468 cells (Fig. S5A) . Furthermore, we performed the ALDEFLUOR assay and found that RANKL significantly increased ALDH positive cells in MDA-MB-468 ( Fig. S5B ). MCF7 cells are not sensitive to RANKL (100 ng/ml, data not shown).
Then, we tested whether p52 directly promotes TAZ transcription. We cloned the TAZ promoter region (−5000 to ATG) based on the Eukaryotic Promoter Database (http://epd.vital-it.ch/index.php) and searched potential p52 binding sites in the TAZ gene promoter region, identifying a p52 binding site from −861 to −851 (Fig. 5B ). To determine whether p52 promotes TAZ transcription directly through this site, we performed a chromatin immunoprecipitation (ChIP) assay using an anti-p100/p52 antibody. As expected, the p52 binding site-containing region was immunoprecipitated by the antibody in both MCF7 and MDA-MB-468 cells. Furthermore, p52 binding was increased by TNF-α stimulation (Fig. 5C ).
Discussion
TNF-α triggers immune reaction and promotes the initiation 9,40,41 , proliferation 42, 43 , survival 44 , invasion 45, 46 and metastasis of tumor cells. However, the mechanism by which TNF-α promotes BCSCs has not been fully elucidated. In this study, we demonstrate that TNF-α increases BCSCs in MCF7 and MDA-MB-468 breast cancer cell lines through induction of TAZ (but not YAP) transcription. Furthermore, TNF-α induces TAZ expression through the non-canonical NF-κB pathway. Activated p100 is processed into p52 by the proteasome, at which time p52 forms homodimers or heterodimers with another transcriptional factor and translocate to the nucleus, binding to the p52 binding site at the TAZ promoter to induce TAZ transcription ( Fig. 6 ). Our findings suggest that TAZ plays a crucial role in inflammatory factor TNF-α-increased BCSCs and could serve as a promising therapeutic target.
For the first time, we discovered there is crosstalk between the non-classical NF-κB pathway and the Hippo pathway. Several lines of evidence support that TNF-α induces IKKα-mediated p100 processing into p52, which is translocated to the nucleus and binds to the TAZ promoter, inducing its transcription. First, TNF-α induces p100, TAZ, and its downstream target gene CYR61 expression at both the mRNA and protein level. Next, TNF-α increases expression of p52 that is processed from p100 by the proteasome, and knockdown of p100 or administration of the proteasome inhibitor MG132 abrogated induction of TAZ by TNF-α. Furthermore, knockdown of IKKα blocked the induction of TAZ and CYR61 although the exact functional mechanism of IKKα is unknown. www.nature.com/scientificreports www.nature.com/scientificreports/ On the one hand, IKKα could phosphorylate p100 to activate its procession. On the other hand, IKKα could phosphorylate H3 in the nucleus 47 to promote TAZ transcription. Finally, RANKL, as a typical non-classical NF-κB pathway activator, also induced expression of TAZ and CYR61.
The correlation between inflammation and cancer has been confirmed by numerous studies. In 1863, Virchow hypothesized the association between cancer and inflammation 48 . To some extent, cancer is a kind of chronic inflammation, and the inflammatory environment supports the development of cancer. In 2008, Frances Balkwill and Alberto Mantovani reported that there were various similarities between tumor and chronic inflammation in the microenvironment 49 . Both immunocytes and inflammatory factors play important roles in tumor development and immunosuppression. TNF-α, a well characterized inflammatory factor, has strong tumor-initiating effects at a low and constant dose. In animal models, blockage of TNF-α and its receptor are strongly antitumor 49 .
It appears that TNF-α increases BCSCs through different mechanisms. In 2010, TNF-α was reported to induce Slug expression by up-regulating HIF1α via the canonical NF-κB pathway, thus promoting BCSCs 18 . In 2012, Li reported that TNF-α up-regulates Twist1 and induces epithelial-mesenchymal transition via the NF-κB pathway 50 . In normal mammary epithelial cells, TNF-α expression levels are very low, whereas TNF-α is over-expressed in most breast tumors 18 . In addition, TNF-α expression levels are significantly positively correlated with recurrence and malignance in these breast cancer patients. In this study under low dose, long-term stimulation, TNF-α increases BCSCs in both MCF7 and MDA-MB-468 cell lines. Importantly, the mechanism of TNF-α-induced BCSCs appears to occur through up-regulation of TAZ expression via the non-canonical NF-κB pathway. TAZ is necessary for TNF-α to increase BCSCs. It has been shown that activated TAZS89A is sufficient to endow CSC-like properties to non-CSCs 27 .
TAZ is an important transcriptional coactivator in the Hippo pathway 18 . High expression levels of TAZ are positively correlated with occurrence and development of cancer 51, 52 . TAZ is tightly regulated in response to a wide range of extracellular and intrinsic signals 53 . Estrogen was reported to activate TAZ through G protein-coupled estrogen receptor 1 (GPER, also known as GPR30) and re-organization of F-actin cytoskeleton 54 . Transcriptional regulation of TAZ has not been well studied. It is reported that up-regulation of TAZ expression occurs during osteogenic differentiation of stromal cells derived from human adipose tissue under hypoxic stress conditions 32 . During bone differentiation of human adipose tissue, TNF-α initiates transcription of TAZ by activating the classical NF-κB pathway, which induces p65 translocation to the nucleus, where it binds to the TAZ promoter. Under hypoxic conditions, HIF-1 directly binds to the HRE site between the second and third exons of TAZ and promotes TAZ mRNA transcription of various breast cancer cell lines 33 . Additionally, the survival rate of breast cancer is negatively correlated with concurrent high-expression of TAZ and HIF-1 33 . Moreover, MRTF/ SRF was reported to induce TAZ transcription in breast cancer cells in response to Heregulin β1 34 . We found that the p52 transcription factor, part of the non-canonical NF-κB pathway 55 , directly induces TAZ transcription in both MCF7 and MDA-MB-468 breast cancer cells in response to TNF-α. Taken together, multiple transcription factors, including HIF-1, SRF, p65, and p52, promote TAZ gene transcription in different contexts. Several questions remain to be addressed in this study. First, since p52 only contains a DNA binding domain but not a transcription activation domain, p52 must be integrated with other factors that have transcriptional activation functionality to form heterodimers. It has been reported that p52 forms heterodimers with RelB or Bcl3 to initiate expression of target genes. In this study, RelB depletion did not influence expression of TAZ induced by TNF-α. Therefore, p52 may activate expression of TAZ by integrating with other distinct transcription factors. Further investigation is required to identify p52 transcriptional factor partners for TAZ induction. In addition, TNF-α significantly induces the expression of p100 in several breast cancer cell lines; however, the molecular mechanism for this is unclear.
In conclusion, we demonstrate that TNF-α launches the cells through a stemness differentiation via up-regulation of TAZ transcription through a non-canonical NF-κB pathway in human breast cancer cell lines. Our findings implicate TAZ as a crucial component in inflammatory factor-promoted breast cancer cells stemness differentiation and suggest that TAZ could serve as a promising therapeutic target in breast cancer. BAY11-7082 is an NF-κB inhibitor, which inhibits TNF-α and induces IκBα phosphorylation. MCF7 cells were treated with BAY11-7082 (2 μM) and then exposed to TNF-α. (E) IKKα knockdown, p100 knockdown, and MG132 block TNF-α induced TAZ and CYR61 mRNA expression in MCF7 cells. Cells were treated with TNF-α or BSA for 48 h. qPCR was performed to detect TAZ, p100, and CYR61 mRNA expression levels. **P < 0.01, t-test. (F) p100 knockdown blocks TNF-α-induced mammosphere increase in MCF7 cells. Cells were transfected with 20 nM p100 siRNA for 48 h and then exposed to 10 ng/ml or 0.1% BSA TNF-α for 48 h. 
Methods
cell culture. Human breast cancer cell lines MCF7 and MDA-MB-468 were purchased from American Type Culture Collection (ATCC). These cell lines have been authenticated with STR assays in 2015 by Conservation Genetics CAS Kunming Cell Bank. These cells were cultured in MEM medium supplemented with 10% fetal bovine serum. All cells were maintained at 37 °C in an incubator with 5% CO 2 . The presence of mycoplasma was routinely tested by PCR to eliminate contamination.
Drugs, reagents and antibodies. TNF-α was purchased from PEPRO TECH (Rocky Hill, USA).
RANKL was purchased from R&D Systems (Minneapolis, MN). Cycloheximide (CHX) was purchased from MP Biomedicals (Irvine, CA, USA). BAY 11-7082, LPS and MG132 were purchased from Sigma-Aldrich (St Louis, MO, USA). The anti-TAZ V386 (25937), anti-CYR61 (3491), anti-p100/p52 (4882), anti-RelA (8242) and anti-RelB (4954) antibodies used for WB were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-tubulin (F7425) and anti-YAP (WH0010413 M1) antibodies were purchased from Sigma-Aldrich. Anti-GAPDH (sc-25778) antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-p100/p52 (ab7972) antibody used for ChIP assays was purchased from Abcam (Cambridge, MA). ALDEFLUOR assay. We performed ALDH assays using an ALDEFLUOR Assay Kit (no. 01700; Stem cell Technologies, Vancouver, BC, Canada) according to the standard protocol. In brief, 25,000 cells were collected and resuspended in 1 ml assay buffer. Next, 5 μl activated reagent was added. Half of the samples (0.5 ml) were immediately put into control tubes with 5 μl DEAB buffer. All samples were incubated for 40 min at 37 °C, after which time they were centrifuged for 5 min at 250 g. Cells were resuspended in 0.5 ml assay buffer and subjected to flow cytometry analysis. CD marker staining assays. 1 × 10 6 cells were collected and resuspended in 1 ml 2% fetal bovine serum PBS. Combinations of fluorochrome-conjugated monoclonal antibodies against human CD44 (FITC; cat. #555478) and CD24 (PE; cat. #555428) were obtained from BD Biosciences (San Diego, California, USA). Primary antibodies or the respective isotype controls (BD Biosciences) were added to the cell suspension and incubated at 4 °C in the dark for 30 min. The cells were washed with clod PBS for three times, were resuspended in 0.5 ml 2% fetal bovine serum PBS and were subjected to flow cytometry analysis. Figure 6 . Schematic of the hypothesis that TNF-α increases BCSCs through up-regulation of TAZ expression via the non-canonical NF-κB pathway. TNF-α induces expression of p100 and activates p100 processing into p52 by IKKα and the proteasome. p52 subsequently binds to a p52 binding site within the TAZ promoter, subsequently up-regulating the latter's transcription. TAZ in turn promotes BCSCs in human breast cancer cell lines.
